Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Abstract: The aim of this study was to test the validation of derivative spectrophotometric
method in simultaneous determination the content amoxicillin and clavulanate potassium in dry
syrup by derivative spectrophotometric method with zero crossing technique, in buffer
phosphate pH 4,4-methanol (91:9) mixture.
The research results were obtained the amoxicillin and clavulanate potassium content at the
second derivative with ∆λ = 2 nm at the wavelength of 239.00 nm and 313.20 nm respectively.
The samples Clavamox® dry syrup were (102.73 ± 8.95)% and Claneksi® (103.52 ± 8.88)% and
clavulanate potassium content of the sample Clavamox ® in dry syrup (97.64 ± 4.12)% and
Claneksi® (95.75 ± 5.64)%. Based on the results of analysis determine the sample content of
amoxicillin and clavulanate potassium compound in dry syrup supply amoxicillin fulfilled the
requirements in United States Pharmacopoeia (USP) 30th edition (2007) and clavulanate
potassium fulfilled the requirement in United States Pharmacopoeia (USP) 30th edition (2007).
The results of validation test on the Clavamox® dry syrup, the percent recovery for the
amoxicillin is 100.43%, relative standard deviation RSD = 0.98% and for clavulanate
potassium, the percent recovery = 100.58%, RSD = 1.46%.
Keywords: Amoxicillin; Clavulanate Potassium; Derivative Spectrophotometry; Zero
Crossing; Second Derivat; Dry syrup; Validation.
Introduction
Amoxicillin is a penicillin derivative antibiotics used to treat infections of the respiratory tract,
gastrointestinal tract and urinary tract. Clavulanate potassium is a form of a salt of clavulanic acid. Clavulanic
acid has antimicrobial working very weak, but can inhibit penicillinase of streptococci and β-lactamase as
gram-negative microbes to bind to the active center of the enzyme. Therefore, these compounds are used in
combination along with β-lactam antibiotics are not stable against β-lactamase1,2. Structur formula of
amoxicillin and clavulanate potassium can be seen in Figure 1 and Figure 2.
According to the United States Pharmacopoeia (USP) 30th3 for amoxicillin and clavulanate potassium
suspension oral is not less than 90.0% and not more than 120.0% of the amount listed on the label.
Determination the result of a mixture of amoxicillin and optimization clavulanate potassium by using
high performance liquid chromatography and detected by ultraviolet spectrophotometer at a wavelength of 220
nm is obtained by comparison of the mobile phase pH 4.4 phosphate buffer-methanol (91:9). Levels of
amoxicillin and clavulanate potassium mixture has also been determined the result of simultaneous
determination of amoxicillin and clavulanate potassium in combined tablets by non-derivative and derivative
ultraviolet spectrophotometric techniques, using aqueous solvent obtained in first derivatives at each
wavelength 244.9 nm and 272 nm. Level of amoxicillin has been determined the result comparative study of
RP-HPLC and UV spectrophotometric techniques for the simultaneous determination of amoxicillin and
cloxacillin in capsules, using water as solvent obtained in first derivatives at each wavelength 258.0 nm4,5,6.
A first-order derivative is the rate of change of absorbance with respect to wavelength. A first order
derivative starts and finishes at zero. It also passes through zero at the same wavelength as λmax of the
absorbance band. Either side of this point are positive and negative bands with maximum and minimum at the
same wavelengths as the inflection points in the absorbance band. This bipolar function is characteristic of all
odd-order derivatives. The most characteristic feature of a second-order derivative is a negative band with
minimum at the same wavelength as the maximum on the zero-order band. It also shows two additional positive
satellite bands either side of the main band. A fourth-order derivative shows a positive band. The first and
second derivatives may be generated using this technique. It is popular for dedicated spectrophotometer designs
used in, for example, environmental monitoring. First-derivative spectra may also be generated by a dual
wavelength spectrophotometer. The derivative spectrum is generated by scanning with each monochromator
separated by a small constant wavelength difference8.
The detection limit of an individual analytical procedure is the lowest amount of analyte in a sample
which can be detected but not necessarily quantitated as an exact value. The quantitation limit of an individual
analytical procedure is the lowest concentration of analyte in a sample which can be quantitatively determined
with suitable precision and accuracy9.
Accordingly, in this research will be conducted as the determination of amoxicillin and clavulanate
potassium in dry syrup by derivative spectrofotometric method with zero-crossing method.
Instrumental
Apparatus
Tools used in this study is UV-Visible spectrophotometer equipped with software Probe 2.42 UV (UV-
1800 Shimadzu), analytical balance (Boeco), cuvette, filter paper, rubber ball, spatula, tools-glassware and
equipment-other tools required in sample preparation.
Siti Morin Sinaga et al /Int.J. PharmTech Res. 2016,9(1),pp 79-89. 81
Reagent
Materials used were methanol, NaH2PO4, distilled water, amoxicillin trihydrate (BPFI) 98.64%,
potassium clavulanate (Phiexia Company) stock 99.70%, Clavamox® and Claneksi® dry syrup.
Sampling
Sampling was done by purposive, which is determined on the basis of the consideration that the
samples drawn have characteristics similar to those studied. The samples used are Clavamox ® dry syrup (PT.
Kalbe) and Claneksi® dry syrup (PT.Sanbe), each of which contains 125 mg of amoxicillin and clavulanate
potassium 31.25 mg.
About 50 mg of amoxicillin were accurately weighed, then diluted with a solvent mixture of phosphate
buffer pH 4.4-methanol (91:9) in a 50 mL flask and paid back with the same solvent to obtain a solution with a
concentration of 1000 µg/mL solution raw I (SS I). From this solution pipette 10 mL, was put into a 100 mL
flask, diluted with a solvent mixture of phosphate buffer pH 4.4-methanol (91:9) to mark the line, shaken until
homogeneous in order to obtain a solution with a concentration of 100 µg/mL solution of the parent Raw II (SS
II).
About 50 mg of clavulanate potassium were accurately weighed, then diluted with a solvent mixture
of phosphate buffer pH 4.4-methanol (91:9) in a 50 mL flask and paid back with the same solvent to obtain a
solution with a concentration of 1000 µg/mL (SS I). From this solution pipette 10 mL, was put into a 100 mL
flask, diluted with a mixture of phosphate buffer pH 4.4-methanol (91:9) to mark the line, shaken until
homogeneous in order to obtain a solution with a concentration of 100 µg/mL (SS II).
Taken as much as 2.0 mL of amoxicillin concentration 100 μg/mL was then inserted into a 10 mL flask
and then diluted with buffer phosphate pH 4,4-methanol (91:9) mixture solvent until the line mark, then shaken
until to obtain a homogeneous amoxicillin solution with a concentration of 20 μg/mL. Absorbance was
measured at a wavelength of 200-400 nm.
Taken as much as 1.65 mL of clavulanate potassium concentration 100 μg/mL was then inserted into
the 10 mL flask to be diluted with buffer phosphate pH 4,4-methanol (91:9) mixture solvent until the line mark,
then shaken until homogeneous to obtain a solution with a concentration of 16.5 μg/mL . Absorbance was
measured at a wavelength of 200-400 nm.
Taken by 1.0 mL; 1.5 mL; 2.0 mL; 2.5 mL; 3.0 mL and 3.5 mL of stock solution amoxicillin
concentration 100 μg/mL (SS II), then each put in a 10 mL flask to be diluted with the solvent buffer phosphate
pH 4,4-methanol (91:9) mixture. Then shaken until homogeneous to obtain a solution with a concentration of
10 μg/mL; 15 μg/mL; 20 μg/mL; 25 μg/mL; 30 μg/mL and 35 μg/mL Then made the absorption spectrum, then
the absorption spectrum is transformed into a first derivative absorption spectrum and the second derivative at a
wavelength of 200-400 nm with Δλ=2nm.
Taken by 0.85 mL; 1.25 mL; 1.65 mL; 2.05 mL; 2.45 and 2.65 mL of stock solution clavulanate
potassium concentration 100 μg/mL (SS II), then each put in a 10 mL flask to be diluted with the solvent buffer
phosphate pH 4,4-methanol (91:9) mixture. Then shaken until homogeneous to obtain a solution with a
concentration of 0.85 μg/mL; 1.25 μg/mL; 1.65 μg/mL; 2.05 μg/mL; 2.45 μg/mL and 2.85 μg/mL. Then made
Siti Morin Sinaga et al /Int.J. PharmTech Res. 2016,9(1),pp 79-89. 82
the absorption spectrum, then the absorption spectrum is transformed into a first derivative absorption spectrum
and the second derivative at a wavelength of 200-400 nm with Δλ=2nm.
Determination of Zero-Crossing
Created amoxicillin solution with a concentration of 35 μg/mL, clavulanate potassium solution with a
concentration of 8.5 μg/mL, and a mixed solution of amoxicillin 35 μg/mL and clavulanate potassium 8.5
μg/mL. Each solution is then measured absorbance at a wavelength of 200-400 nm. Then absorption spectrum
is transformed into the first and second derivatives of each single substance from a mixture of amoxicillin and
clavulanate potassium. The second derivative absorption spectrum from a single substance solution and a
mixture of both overlay. Were chosen to be the wavelength analysis is that at a particular wavelength, the
absorption single one of the compounds zero while single absorption partner compound and a mixture of both is
almost the same or exactly the same. Because at these wavelength can selectively measure the uptake of one of
the compounds without being bothered by the uptake of compounds partner.
Preparation and Determination Linearity Calibration Curves Amoxicillin and Clavulanate Potassium
Created amoxicillin stock solution with a concentration of 10 μg/mL; 15 μg/mL; 20 μg/mL; 25 μg/mL;
30 μg/mL and 35 μg/mL, then the second derivative absorption measured (Δλ = 2 nm) in wavelength analysis
has been determined. Then do the analysis of the relationship between concentration and absorbance values thus
obtained linear regression equation y = ax+b. And based on the absorption at a wavelength analysis, also
conducted the calculation of the Limit of Detection (LOD) and the Limit of Quantitaion (LOQ). To determined
the LOD and the LOQ can be used formula.
å (Y - Yi )
2
SD =
n-2
3 ´ SD
LOD =
slope
10´ SD
LOQ =
slope
Description:
SD = Standard Deviation
LOD = Limit of Detection
LOQ = Limit of Quantitation
One bottle of dry syrup powder weighed. Then weighed carefully the amount of powder equivalent to
50 mg of amoxicillin and then the weight of which weighed analyte equivalent of 50 mg of amoxicillin
clavulanate potassium is calculated equality contained therein (powder weighing as much as six times
repetition), put in a 50 mL flask, added phosphate buffer pH 4.4-methanol (91:9) to line sign while shaken. The
solution is then homogenized with an ultrasonic stirrer for 15 minutes. The solution is then filtered,
approximately 10 mL of the first filtrate discarded. The filtrate subsequently accommodated. Then from this
filtrate solution, 0.35 mL pipette and put into a flask and diluted with 10 mL of phosphate buffer pH 4.4-
methanol (91:9) to mark the line (concentration of 35 µg/mL for amoxycillin and concentrations of 8,5 µg/mL
for clavulanate potassium). The solution is measured at the second derivative absorbance at a wavelength
analysis has been determined to amoxicillin and clavulanate potassium. Furthermore, the absorbance was
measured at a wavelength of 200-400 nm, then the absorption spectrum is transformed into a second derivative
Siti Morin Sinaga et al /Int.J. PharmTech Res. 2016,9(1),pp 79-89. 83
Validation Test
Accuracy Test
Accuracy test was conducted by the addition of raw materials is to make three samples with the analyte
concentration of a specific range of 80%, 100%, 120%. Where in each specific range is used 70% and 30% of
raw samples to be added and then mix the sample and standard absorbance was measured at a wavelength of
200-400 nm, then the absorption spectrum is transformed into a second derivative absorption spectrum Δλ 2 nm
in wavelength analysis of amoxicillin and clavulanate potassium respectively 239.00 nm and 313.20 nm.
Percentage recovery can be calculated by the formula10.
% Recovery = 100 %
Description:
CF = concentration of the substance after the addition of raw materials
CA = concentration of the substance before adding the raw materials
C*A = number of raw added
Precision Test
Based on the results of recovery prescribed amoxicillin and clavulanate potassium standard deviation
amoxicillin and clavulanate potassium of the formula:
SD =
Description:
X = The number of substances in the sample
X = Number of substances sample average
n = Number of repetitions
Standart Deviation (SD) obtained based on the value, calculated relative standard deviation of amoxicillin and
clavulanate potassium by the formula:
RSD = x 100%
Description:
X = Number of substances sample average
SD = Standard deviation
RSD = Relative Standard Deviation
Siti Morin Sinaga et al /Int.J. PharmTech Res. 2016,9(1),pp 79-89. 84
0.00000
Abs.
-0.04000
-0.05000
200.00 250.00 300.00 350.00 400.00
nm.
Figure 3. Overlapping absorption spectrum of amoxicillin and clavulanate potassium at first derivative at
wavelength 239.00 nm and 313.20 nm respectively.
Results of the second derivative absorption spectrum determination is made by first making the
absorption spectrum of amoxicillin solution with a concentration of 35 µg/mL and clavulanate potassium with a
concentration of 8.5 µg/mL at a wavelength of 200-400 nm. Absorption spectra have been obtained is
transformed into a second derivative absorption spectrum with Δλ = 2 nm.
The second derivative absorption spectrum of respectively of these substances overlay. The results
indicate zero crossing at a wavelength of 239.00 nm, 246.80 nm, and 249.60 nm to amoxicillin, whereas for
clavulanate potassium was obtained at a wavelength of 263.40 nm, 313.20 nm and 320.60 nm. Wavelength and
absorbance analysis can be seen in Table 1 and overlapping absorption spectrum of amoxicillin and clavulanate
potassium on the second derivative in Figure 4.
Wavelength Absorbance
(nm) Amoxicillin Clavulanate Amoxicillin and
35.0 μg/mL Potassium 8,5 μg/mL Clavulanate Potassium
239,00 0,0004 0,0000 0,0003
246,80 0,0005 0,0000 0,0004
249,60 0,0003 0,0000 0,0005
263,40 0,0000 0,0004 0,0004
313,20 0,0000 0,0005 0,0005
320,60 0,0000 0,0001 0,0001
Siti Morin Sinaga et al /Int.J. PharmTech Res. 2016,9(1),pp 79-89. 85
0.00500
0.00000
Abs.
-0.00500
-0.00750
200.00 250.00 300.00 350.00 400.00
nm.
Figure 4. Overlapping absorption spectrum of amoxicillin and clavulanate potassium on the second
derivative at wavelength 239.00 nm and 313.20 nm respectively.
0.00100 239.0 nm
Abs.
0.00050
0.00000
-0.00050
233.53 235.00 240.00 245.00 250.00
nm.
0.00 150
0.00 100
313.2 n m
bs.
0.00 050
A
0.00 000
-0.00 050
30 7.1 9 310.00 315.00 320 .0 0 325.00 328.14
nm.
Determination of the wavelength of the analysis done by making a solution of amoxicillin 35 µg/mL, a
solution of clavulanate potassium 8.5 µg/mL and mixed solution of amoxicillin 35 µg/mL and clavulanate
potassium 8.5 µg/mL. Then made the absorption spectrum of the first and second derivatives, then overlaid. To
Siti Morin Sinaga et al /Int.J. PharmTech Res. 2016,9(1),pp 79-89. 86
determine the wavelengths of the absorption spectrum analysis on each derivative is done by observing the
absorption wavelength shows zero partner compounds and other compounds uptake and absorption thereof has
a value equal or nearly equal. Amoxicillin wavelength spectrum analysis, and the wavelength spectrum analysis
each clavulanate potassium can be seen in Figures 5 and 6.
Based on the above image, obtained by the wavelength used for the determination of the mixture of
amoxicillin and clavulanate potassium uptake is on the second derivative, is 239.00 nm for amoxicillin, and
313.20 nm for clavulanate potassium. It is known based wavelength selection for each derivative analysis. The
wavelength of the analysis is obtained by determining the zero crossing for amoxicillin and clavulanate
potassium. At first derivative absorption, wavelength analysis for amoxicillin can be found. However, the
wavelength analysis for clavulanate potassium was not found, so the assay mixture of amoxicillin and
clavulanate potassium performed on the second derivative.
The linearity of the calibration curve showed a linear relationship between the absorbance with
concentration. Amoxicillin regression equation, Y = (7X + 0.25).10-6 with a correlation coefficient, r = 0.9995
and clavulanate potassium, Y = (21X + 1.35).10-6 with a correlation coefficient, r = 0.9997. R values > 0.995
showed a linear correlation relationship between X and Y11. The calibration curve amoxicillin and clavulanate
potassium for each wavelength of 239.00 nm and 313.20 nm can be seen in Figures 5 and 6.
Standard Curve
0.00028
0.00020
Abs.
0.00010
0.00000
-0.00003
0.00000 10.00000 20.00000 30.00000 35.00000
Conc. (mg/l)
0.00040
Abs.
0.00020
0.00000
-0.00006
0.00000 10.00000 20.00000 28.50000
Conc. (mg/l)
Determination is done by using Clavamox® and Claneksi® in dry syrup containing amoxicillin 125
mg and 31.25 mg potassium clavulanate. Measurement of amoxicillin and clavulanate potassium raw on both
Siti Morin Sinaga et al /Int.J. PharmTech Res. 2016,9(1),pp 79-89. 87
substances each amoxicillin and clavulanate potassium 35µg/mL and 8.5 µg/mL, which is adapted to the
content ratio of the two substances in the preparation, namely 125:31.25 or 4:1.
The prepared sample is then measured at a wavelength of 200-400 nm. Furthermore, the results of the
absorption spectrum is transformed into a second derivative absorption spectrum with Δλ = 2 nm. Can be
determined based on the absorbance spectrum of amoxicillin and clavulanate potassium at a wavelength
analysis has been obtained previously, is wavelengths 239.00 nm and 313.20 nm. Levels of amoxicillin and
clavulanate potassium in Clavamox® and Claneksi® can be seen in Table 2.
Amoxicillin and clavulanate potassium levels obtained in the above table shows that the dry syrup
preparation Clavamox® and Claneksi® on the market meet the requirement in the Farmakope Indonesia Edisi
V12, which is not less than 90% and not more than 120% of the amount listed on the label.
Validation parameters tested were accuracy, precision, limits of detection and quantitation limits.
Accuracy is expressed in percent recovery were determined using standard addition method. Precision test done
using parameters Relative Standard Deviation (RSD)10.
Accuracy Test
Accuracy test with parameter percent recovery is done by using Clavamox® in dry syrup with
standard addition method, which is made by adding a certain amount of standard solution. Then the solution is
measured in accordance absorbance wavelength analysis, which is 239.00 nm and 313.20 nm. Results recovery
of amoxicillin and clavulanate potassium by standard addition method standard Clavamox ® in dry syrup can be
seen in Table 3.
Based on the results obtained in Table 4 shows that the average percent recovery obtained for
amoxicillin is 100.43% and 100.58% for clavulanate potassium. The results obtained are eligible for the
accuracy of the validation of analytical procedures because the average is between the range of 98-102%9.
Precision Test
Precision test is done by calculating the relative standard deviation. Based on the calculation of data on
levels of amoxicillin and clavulanate potassium, obtained relative standard deviation is 0.98% for amoxicillin
and clavulanate potassium 1.46%. The relative standard deviation of the results of the two substances which
meet the requirements of ≤2%9.
Conclusion
Based on the research conducted, it can be concluded spectrophotometric method with zero crossing
derivatives can be used to set the levels of amoxicillin and clavulanate potassium. Levels of amoxicillin and
clavulanate potassium in dry syrup preparation Clavamox ® and Claneksi® meet the requirements of an oral
suspension levels according to the Farmakope Indonesia edisi V11. Validation test conducted on dry syrups
Clavamox® showed that the spectrophotometric method of derivatives meet the requirements validation, which
includes parameters of accuracy and precision.
References
1. Sweetman, S.C. Martindale the Extra Pharmacopeia. 36th edition. London: Pharmaceutical Press.
2009: 202.
2. Kuroki, H., Ishiwada, N., Inoue, N., Ishikawa, N., dan Suzuki, H. Comparison of Clinical Efficacy
Between 3-Day Combined Clavulanate/Amoxicillin Preparation Treatment 10-Day Amoxicillin
Treatment in Children with Pharyngolaryngitis or Tonsilitis. Journal of Cystic Fibrosis. 2013: 12(6);
780-783.
3. United State Pharmacopoeia. The National Formulary. 30 th edition. The United States Pharmacopoeia
Convention. 2007: 1406.
4. Martina, A. Optimasi Fase Gerak Dapar Fosfat pH 4,4-Metanol pada Penetapan Kadar Campuran
Amoksisilin dan Asam Klavulanat dalam Tablet dengan Kromatografi Cair Kinerja Tinggi (KCKT).
Medan: Fakultas Farmasi Universitas Sumatera Utara. 2010: 34, 42.
5. Huong, V.T. dan Hoang, V.D. Simultaneous Determination of Amoxicillin and Clavulanate in
combined tablets by non-derivative and derivative UV spectropotometric techniques. International
Journal of Pharmtech Research. 2009: 1(4): 1173-1181.
6. Giang, D.T dan Hoang, V.D. Comparative Study of RP-HPLC and UV Spectrophotometric
Techniques for the Simultaneous Determination of Amoxicillin and Cloxacillin in Capsules. J Young
Pharm. 2010: 2(2); 190-195.
7. Talsky, G. Derivative Spectrophotometric. Low and Higher Order. Weinheim Germany: VCH
VerlagsgesellschaftmbH. 1994: 16 - 43.
8. Owen, A.J. Uses of Derivative Spectroscopy Aplication Note UV - Visible Spectroscopy. HP Way:
Agilent Technologies. 1995
9. Ermer, J., dan McB. Miller, J. H. Method Validation in Pharmaceutical Analysis, A Guide to Best
Practice. Weinheim: Wiley-Vch Verlag GmbH & Co. KGaA. 2005: 99.
Siti Morin Sinaga et al /Int.J. PharmTech Res. 2016,9(1),pp 79-89. 89
10. ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology
Q2(R1). International Conference on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use. 2005: 6-13.
11. Watson, D.G. Pharmaceutical Analysis: A Textbook for Pharmacy Students and Pharmaceutical
Chemists. 2 edition. Jakarta: EGC. 2000: 126.
12. Ditjen POM. Farmakope Indonesia edisi V. Jakarta: Departemen Kesehatan RI. 2014: 126, 652.
*****